Zacks.com on MSN6d
Cytokinetics (CYTK) Moves 5.4% Higher: Will This Strength Last?Cytokinetics (CYTK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...
NLST's Q4 performance is shaped by a rich patent portfolio and notable legal victories amid a declining gross margin and ...
Zacks Investment Research on MSN2d
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should KnowAmgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...
AAR Corp. (AIR) on Thursday reported a fiscal third-quarter loss of $8.9 million, after reporting a profit in the same ...
Zacks Investment Research on MSN2d
UiPath, Inc. (PATH) Is a Trending Stock: Facts to Know Before Betting on ItUiPath (PATH) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...
If you're serious about swing trading, the real-time tools in FINVIZ*Elite could be a game-changer. Since 1978, Zacks Investment ... We used this data to review each platform for pricing ...
Research analysts at Zacks Research boosted their Q1 2027 EPS estimates for shares of Guidewire Software in a research note ...
Stock analysts at Zacks Research lowered their Q1 2025 earnings per share estimates for shares of Stratasys in a research ...
Stocks in Japan tumbled nearly 4 percent as investors braced for a week of market turmoil caused by an expected announcement ...
Brad Setser, a senior fellow at the Council on Foreign Relations, says the U.S. is headed for a recession — though not a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback